

# Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

Srdan Verstovsek,<sup>1</sup> Ruben Mesa,<sup>2</sup> Moshe Talpaz,<sup>3</sup> Jean-Jacques Kiladjian,<sup>4</sup> Claire N. Harrison,<sup>5</sup> Stephen T. Oh,<sup>6</sup> Alessandro M. Vannucchi,<sup>7</sup> Raajit Rampal,<sup>8</sup> Bart L. Scott,<sup>9</sup> Sarah A. Buckley,<sup>10</sup> Adam R. Craig,<sup>10</sup> Karisse Roman-Torres<sup>10</sup> and John O. Mascarenhas<sup>11</sup>

<sup>1</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Mayo Clinic, Scottsdale, AZ, USA; <sup>3</sup>University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA; <sup>4</sup>Hôpital Saint Louis, Université Paris Diderot, Paris, France; <sup>5</sup>Guy's and St Thomas' NHS Foundation Trust, London, UK; <sup>6</sup>Washington University School of Medicine, St. Louis, MO, USA; <sup>7</sup>University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy; <sup>8</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>9</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>10</sup>CTI BioPharma Inc, Seattle, WA, USA and <sup>11</sup>Icahn School of Medicine at Mount Sinai, New York, NY, USA

**Correspondence:** S. Verstovsek  
[srdanverstovsek@gmail.com](mailto:srdanverstovsek@gmail.com)

**Received:** December 5, 2023.

**Accepted:** December 5, 2023.

<https://doi.org/10.3324/haematol.2023.284815>

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license



An error was published in Table 2, row 5 of our manuscript in the July issue 2022 of Haematologica.<sup>1</sup> The number for the Pacritinib group was erroneously published as 17.9 (5/28) and should be 25.0 (19/76). The corrected Table 2 is shown here.

**Corrected Table 2.** Spleen volume response and modified Total Symptom Score response rates among patients randomized to pacritinib versus best available therapy by subgroup: prior exposure to a JAK2 inhibitor (including ruxolitinib) and myelofibrosis subtype (primary vs. secondary after a prior diagnosis of polycythemia vera or essential thrombocythemia).

Response rate at week 24	Pacritinib	BAT	P*
<b>Patients with ≥35% spleen volume reduction, % (n/N)</b>			
Prior JAK2 inhibitor exposure			0.07
Yes	17.9 (5/28)	7.7 (1/13)	
No	25.0 (19/76)	0 (0/35)	
MF diagnosis			0.52
Primary	24.0 (18/75)	3.1 (1/32)	
Secondary	20.7 (6/29)	0 (0/16)	
<b>Patients with a ≥50 reduction in modified TSS, % (n/N)</b>			
Prior JAK2 inhibitor exposure			0.14
Yes	17.9 (5/28)	15.4 (2/13)	
No	28.8 (15/52)	4.2 (1/24)	
MF diagnosis			0.43
Primary	30.4 (17/56)	12.5 (3/24)	
Secondary	12.0 (3/25)	0 (0/12)	
<b>Patients with “much” or “very much” improved PGIC scores, % (n/N)</b>			
Prior JAK2 inhibitor exposure			0.08
Yes	14.3 (4/28)	15.4 (2/13)	
No	28.9 (22/76)	5.7 (2/35)	
MF diagnosis			0.45
Primary	30.7 (23/75)	12.5 (4/32)	
Secondary	10.3 (3/29)	0 (0/16)	

BAT: best available therapy; JAK2: Janus kinase 2; MF: myelofibrosis; PGIC: Patient Global Impression of Change; TSS: Total Symptom Score.  
 \*Breslow and Day homogeneity test.

## References

- Verstovsek S, Mesa R, Talpaz M, et al. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. *Haematologica*. 2022;107(7):1599-1607.